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Endothelin Genes among children with and
without Endothelial Dysfunction
Siriporn Chatsuriyawong1,2, David Gozal1, Leila Kheirandish-Gozal1, Rakesh Bhattacharjee1, Ahamed A Khalyfa1,
Yang Wang1, Hakon Hakonarson3, Brendan Keating3, Wasana Sukhumsirichart2 and Abdelnaby Khalyfa1*Abstract
Background: The presence of endothelial dysfunction (ED) constitutes an early risk factor for cardiovascular disease
(CVD) in children. Nitric oxide (NO) and endothelin (EDN) are generated in endothelial cells and are critical regulators of
vascular function, with ED resulting from an imbalance between these two molecules. We hypothesized that genetic
variants in NO synthase and EDN isoforms and its receptors (EDNRA and EDNRB) may account for a proportion of the
risk for ED in developing children.
Methods: Consecutive children (ages 5–10 years) were prospectively recruited from the community. Time to peak post-
occlusive reperfusion (Tmax) was considered as the indicator of either normal endothelial function (NEF; Tmax < 45 sec)
or ED (Tmax ≥ 45 sec). Lipid profiles, high sensitivity C-reactive protein (hsCRP), fasting glucose and insulin were assayed
using ELISA. Genomic DNA from peripheral blood was extracted and genotyped for NOS1 (209 SNPs), NOS2 (122 SNPs),
NOS3 (50 SNPs), EDN1 (43 SNPs), EDN2 (48 SNPs), EDN3 (14 SNPs), EDNRA (27 SNPs), and EDNRB (23 SNPs) using a
custom SNPs array. Linkage disequilibrium was analyzed using Haploview version 4.2 software.
Results: The relative frequencies of SNPs were evaluated in 122 children, 84 with NEF and 38 with ED. The frequencies
of NOS1 (11 SNPs), and EDN1 (2 SNPs) were differentially distributed between NEF vs. ED, and no significant differences
emerged for all other genes. Significant SNPs for NOS1 and EDN1 SNPs were further validated with RT-PCR.
Conclusions: Genetic variants in the NOS1 and EDN1 genes appear to account for important components of the
variance in endothelial function, particularly when concurrent risk factors such as obesity exist. Thus, analysis of
genotype-phenotype interactions in children at risk for ED will be critical for more accurate formulation of categorical
CVD risk estimates.
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Obesity is one of the world’s greatest public health chal-
lenges affecting not only developed, but also developing
countries. The presence of obesity has now been conclu-
sively linked to heightened morbidity and mortality
through increased risk for many chronic diseases, includ-
ing type-2 diabetes, hypertension, dyslipidemia, and cor-
onary artery disease [1-4]. The pathogenesis of obesity is* Correspondence: akhalyfa@uchicago.edu
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distribution, and reproduction in any mediummultifactorial incorporating both genetics and lifestyle. In
children, obesity is associated with increased risk for
multifaceted derangements in metabolic and cardiovascu-
lar function, including endothelial dysfunction (ED) [5-8].
In general terms, overweight children are more likely to
prematurely develop ED, hypertension and type 2 diabetes,
an array of conditions that would normally be only found
in older obese adults [4]. Recently, we have shown that
obesity in children is associated with an increased risk for
the development of ED prior to the onset of hypertension
[7]. However, not every obese child will develop ED,
suggesting that both genetic and environmental factors
may play a role. Conversely, a small subset of otherwiseCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mal endothelial function, and such functional phenotype
may be determined by genetic variance in endothelial
function-related genes.
ED, an early risk marker of cardiovascular disease, re-
fers to a loss of normal homeostatic function in the
blood vessels and is characterized by altered vasodilatory
and vasoconstrictive functions and inflammatory activity
[9]. ED is involved in the development of vascular com-
plications related to dyslipidemia, and cardiovascular
disease such as hypertension, coronary artery disease
and chronic heart failure [10,11]. A major contributor of
ED involves reductions in the amount of bioavailable ni-
tric oxide (NO) in the vasculature [12]. Indeed, NO is an
important factor in endothelial functional homeostasis,
and also inhibits platelet aggregation, leukocyte adhe-
sion, smooth muscle cell migration and proliferation
[13], as well as oxidation of atherogenic low-density
lipoprotein [14]. NO is synthesized from the amino acid
L-arginine in endothelial cells, as well as many other cell
types by three nitric oxide synthase (NOS) isoforms;
neuronal (nNOS, NOS1), inducible (iNOS, NOS2), and
endothelial (eNOS, NOS3) [15-18]. NOS1 and NOS3
genes are constitutively expressed resulting in a low basal
synthesis of NO [19,20], whereas induction of NOS2 ex-
pression is regulated by transcription factors such as
nuclear factor κB (NF-KB) [21]. Several studies have
examined the possibility that genetic variants in the genes
encoding these enzymes could influence their expression
and functional activity, potentially altering the predispos-
ition to cardiovascular disease [22,23]. Accordingly, single
nucleotide polymorphisms (SNPs) have been identified in
NOS genes, and their association with coronary artery
disease, hypertension, and diabetes has been explored
[24-26]. To the best of our knowledge, the potential as-
sociations between NOS polymorphisms and ED are cur-
rently unexplored in children.
The endothelin (EDN) system consists of three endo-
thelin isoforms (EDN1, EDN2 and EDN3), and two re-
ceptors (endothelin type A and type B) linked to
multiple signaling pathways [27]. Endothelins (EDN1,
EDN2 and EDN3) are 21-amino acid peptides that exert
their effects through their cognate receptors EDNRA
and EDNRB with different degrees of binding affinity.
Various SNPs have been identified on EDN genes and
EDNRA and EDNRB receptors genes, and have been as-
sociated with susceptibility and prognosis of diseases
such as heart failure, dilated cardiomyopathy, diabetic
retinopathy, and atherosclerosis [28-32]. Again, we are
unaware of any published studies on the potential asso-
ciations between ED and endothelin-related gene vari-
ants in children.
Based on aforementioned considerations, we aimed to
identify single nucleotide polymorphisms (SNPs) in NOSfamily (3 isoforms), and EDN family (3 isoforms and
their 2 cognate receptors) in order to identify potential
associations of these SNPs with ED in children.
Methods
Subjects
The study was approved by the University of Louisville
Human Research Committee (Louisville, KY, USA), and
informed consent was obtained from the legal caregiver
of each participant. Consecutive healthy pre-pubertal
children (ages 5–10 years) were recruited from the com-
munity to investigate endothelial function.
Anthropometric characteristics
Anthropometry
Children were weighed using the InBody 320 scale
(Biospace; Cerritos, CA), and height (to 0.1 cm) was mea-
sured using a stadiometer (Holtain, Crosswell, UK). The
BMI was calculated and the BMI z-score was computed
using US Centers for Disease Control and Prevention
2000 growth standards (http://www.cdc.gov/growthcharts/)
and online software (http://wwwn.cdc.gov/epiinfo/). A
BMI z-score > 1.65 (> 95th percentile) was considered as
fulfilling obesity criteria.
Sphygmomanometry
All children had arterial blood pressure measured nonin-
vasively using an automated mercury sphygmomanom-
eter (Welch Allyn; Skaneateles Falls, New York) at the
brachial artery, using the appropriate cuff size on the
nondominant arm [33]. Systolic BP and diastolic BP
indices were calculated by dividing the average sys-
tolic and diastolic pressure by the respective 95th per-
centile for BP using National Heart, Lung and Blood
Institute guidelines http://www.nhlbi.nih.gov/guidelines/
hypertension/child_tbl.htm), computed for age, sex, and
height. Hypertension was defined when the SBPi or DBPi
was > 1.
Endothelial function tests
Endothelial function was assessed using a modified
hyperemic test after cuff-induced occlusion of the radial
and ulnar arteries by placing the cuff over the wrist. All
testing was performed in the morning after an overnight
fast. A laser Doppler sensor (Periflux 5000 System inte-
grated with the PF 5050 Pressure Unit, Perimed, Järfälla,
Sweden) was applied over the volar aspect of the hand at
the 1st finger distal metacarpal surface and the hand was
gently immobilized. This site was chosen as an area in
order to minimize the effects of motion artifact, and was
also found to have a density of skin capillary blood flow
that was of appropriate magnitude for detection. Chil-
dren lay supine with the head of the bed elevated 45°.
Once cutaneous blood flow over the area became stable,
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arm and connected to a computer- controlled manom-
eter was raised to 200 mmHg for 60 seconds during
which blood flow was reduced to undetectable levels. An
occlusion time of 60 seconds was chosen in order to
minimize discomfort for the child and thus prevent mo-
tion and invalidation of the test. Furthermore, we used a
computer-controlled pressure release to allow for con-
sistent deflation times. The cuff was rapidly deflated,
and the laser Doppler measured hyperemic responses.
The maneuver was repeated twice within 10 min with at
least 2 min separating both trials to ensure a return to
baseline perfusion. The average of both maneuvers was
then computed for subsequent analyses, and demon-
strated excellent reproducibility [34]. Commercially avail-
able software (Perimed, Järfälla, Sweden) allowed for
unbiased estimates of the time to peak regional blood flow
response post-occlusion release (Tmax), which is consid-
ered representative of the hyperemic response and an
index of endothelial function [35]. As previously de-
scribed, we defined abnormal endothelial function as a
Tmax cutoff value of ≥45 seconds [34].Plasma assays
Fasting blood samples were drawn from the subjects and
immediately centrifuged in a cooled centrifuge and plasma
was frozen at −80°C until assay, usually within <2 weeks
from collection. Plasma insulin levels were measured
using a commercially available radioimmunoassay kit
(Coat-A Count Insulin; Diagnostic Products Inc). This
method has a detection level of 1.2 μIU/mL and exhibits
linear behavior up to 350 μIU/mL, with intra-assay and
inter-assay coefficients of variability of 3.1% and 4.9%,
respectively. Plasma glucose level was measured using a
commercial kit based on the hexokinase-glucose-
6-phosphate dehydrogenase method (Flex Reagent
Cartridges; Dade Behring, Newark, DE). Insulin resist-
ance was assessed using the homeostasis model assess-
ment (HOMA) equation (fasting insulin × fasting
glucose/22.5) [36]. Plasma hsCRP levels were measured
within 2–3 hours after collection using the Flex reagent
Cartridge (Date Behring, Newark, DE). This method has
a detection level of 0.05 mg/dl, and exhibits linear be-
havior up to 255 mg/dl, with intra-assay and inter-assay
coefficients of variability of 9% and 18% respectively for
hsCRP. Serum lipids including total cholesterol, high-
density lipoprotein (HDL) cholesterol, calculated low-
density lipoprotein cholesterol (LDL), and triglycerides
(TG) were also assessed using Flex Reagent Cartridges
(Dade Behring). To ensure consistency and to prevent
protein degradation, particular care was taken to
standardize all steps of plasma sample processing and
to minimize thawing more than once for each aliquot.DNA extraction
Peripheral blood samples were collected in vacutainer
tubes containing EDTA (Becton Dickinson, Franklin
Lakes, NJ, USA). Genomic DNAs of children were ex-
tracted using QIAmp DNA blood kit (Qiagen, Valencia,
CA, USA). The concentration and quality of the DNA
were determined using a ND-1000 Spectrophotometer
(Nanodrop Technologies, Wilmington, DE, USA). The
purity of the DNA were determined by calculating the
ratio of absorbance at 260/280 nm, and all DNA samples
had a ratio of 1.8–1.9. The precise length of genomic
DNA was determined by gel electrophoresis using 1%
agarose gel. All the purified samples were stored at −80°
C until further analyses.
Custom cardiovascular gene SNP array
The IBC array was developed using SNP and linkage dis-
equilibrium information from the HapMap as well as
resequencing data from Seattle SNPs and National Insti-
tute of Environmental Health Sciences (NIEHS) SNPs
[37]. Briefly, the IBC array contains about 50,000 SNPS
from genetic diversity across approximately 2100 genes
related to cardiovascular, inflammatory, hemostasis/co-
agulation, and metabolic phenotypes and pathways.
Among those genes, we selected the NOS genes which
include NOS1 (209 SNPs), NOS2 (122 SNPs) and NOS3
(50 SNPs). Furthermore we selected the EDN and EDN
receptor genes family which includes EDN1 (43 SNPs),
EDN2 (48 SNPs), EDN3 (14SNPs), EDNRA (27 SNPs)
and EDNRB (23 SNPs). SNPs were clustered into geno-
types with the Illumina Beadstudio software and
subjected to quality-control filters at the sample and
SNP levels separately within each cohort. Samples were
excluded for individual call rates <90%, gender mis-
match, and duplicate discordance. SNPs were removed
for call rates <95% or Hardy-Weinberg Equilibrium p <
10−7 in controls from each cohort (regardless of ethni-
city). Because of the low-frequency SNPs included in the
design and the aim to capture low-frequency variants of
large effect across the large dataset, we filtered only on
minor allele frequency (MAF) < 0.005.
Validation of SNP array using real-time PCR
SNPs that showed statistically significant differences
between children with ED and without ED were fur-
ther validated using TaqMan real-time PCR (Applied
Biosystems, Inc.). Two fluorogenic minor groove binder
probes were used for each locus using the dyes 6-
carboxyfluorescein (FAM; excitation, 494 nm) and VIC
(excitation, 538 nm) which are easily differentiated in RT-
PCR system. The reaction mixture (25 μl total volume per
single well reaction) containing 12.5 μl of TaqMan 2X uni-
versal master mix (Applied Biosystems, CA), 1.25 μl of
each primer, 10.25 μl of RNase- and DNase-free water
Table 1 Demographic characteristics and metabolic data
in children with and without endothelial dysfunction
Variables Endothelial
function
Endothelial
dysfunction
P-value
(n = 84) (n = 38)
Age (years) 7.60 ± 1.22 8.05 ± 1.32 0.14
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sample was duplicated in two wells of a 96 well-plate
(Applied Biosystems, CA). DNase-free water used as
negative control was included in each assay run. Proto-
col consisted of 2 min at 50°C, 10 min at 95°C, and 42
cycles of 95°C for 15 sec and 60°C for 1 min. Initially,
the SNP assay was set up using SDS, version 2.1, soft-
ware (Applied Biosystems, CA) as an absolute quantifica-
tion assay, but after assay completion the plate was read
using the allelic discrimination settings. Post-assay ana-
lysis was performed using the SDS software. The
goodness-of-fit test for Hardy–Weinberg equilibrium
(HWE) was performed after analysis using the equation
p2 + q2 + 2pq = 1, where p and q represent the wild-type
and variant allele of a gene.
Total RNA isolation
Fasting peripheral blood samples were drawn from chil-
dren within the first hour after awakening and collected
in PAXgene Blood RNA tubes (Becton Dickinson, UK).
Total RNA was isolated using PAXgene Blood RNA Kit
and treated with DNase I (QIAGEN, CA), according to
the manufacturer’s protocol. The RNA quantity and in-
tegrity were determined using a Nanodrop Spectropho-
tometer and Agilent 2100 Bioanalyzer Nano 6000
LabChip assay (Agilent Technologies).
Gene expression using qRT-PCR
Quantitative real time RT-PCR (qRT-PCR) analyses were
performed using ABI 7500 (Applied Biosystems, Foster
City, CA). cDNA synthesis was performed using a High-
Capacity cDNA Archive Kit (Applied Biosystems, FosterRecruited Children
n= 850 
Excluded Children  
n= 245
Included in the study 
n= 605 
Endothelial Function  
n= 122
Normal Endothelial Function  
n= 84
Endothelial Dysfunction  
n= 38
Figure 1 Schematic diagram illustrating the recruitment
process. Children were matched for age, gender and ethnicity.
Children were excluded from the study, if they had any chronic
medical conditions such as known genetic syndromes, severe
asthma or allergies, or if they were on any chronic medications.City, CA). Five hundred nanograms (500 ng) of total
RNA from NEF and ED samples were used to generate
cDNA templates for RT-PCR. The TaqMan® Master Mix
Reagent Kit (Applied Biosystems, Foster City, CA) was
used to amplify and quantify each transcript of interest
in 25 μl reactions. Various negative controls were in-
cluded in the PCR reaction to ensure specific amplifica-
tion. Triplicate PCR reactions were performed in 96-well
plates for each gene in parallel with the 18S rRNA. The
steps involved in the reaction program included: the ini-
tial step of 2 minutes at 50°C; denaturation at 95°C for
10 min, followed by 45 thermal cycles of denaturation
(15 seconds at 95°C) and elongation (1 min at 60°C).
The expression values were obtained from the cycle
number (Ct value) using the Biosystems analysis soft-
ware. The threshold cycle (CT) values were averaged
from each reaction, and each gene was normalized to
the 18S rRNA level. All the genes of interest and 18S
rRNA were performed in triplicates to determine the Ct-
diff. These Ct values were averaged and the difference
between the 18S Ct (Avg) and the gene of interest Ct
(Avg) was calculated (Ct-diff ). The relative expression of
the gene of interest was analyzed using the 2-ΔΔCT
method [38]. Quantitative results are expressed as theGender (% male) 70.2 63.2 0.16
Ethnicity
White Caucasian % 77.9 74.3 0.19
African American % 22.1 25.7 0.22
1BMI z-score 0.99 ± 1.26 1.75 ± 0.98 0.0002
2SBP (mmHg) 105.35 ± 10.84 105.31 ± 11.12 0.50
3DBP (mmHg) 62.60 ± 7.57 62.11 ± 7.70 0.40
4Tmax (sec) 27.47 ± 10.65 61.97 ± 16.92 0.0001
5TG (mg/dl) 71.69 ± 36.42 88.97 ± 52.80 0.04
6TC (mg/dl) 160.60 ± 25.99 166.72 ± 27.12 0.13
7HDL-C (mg/dl) 52.77 ± 10.46 49.67 ± 8.66 0.05
8LDL-C (mg/dl) 93.19 ± 22.11 99.22 ± 23.68 0.10
Glucose (mg/dl) 78.72 ± 16.48 80.59 ± 13.63 0.28
Insulin (mg/dl) 6.44 ± 5.34 8.77 ± 6.53 0.05
9HOMA-IR 1.12 ± 1.21 1.27 ± 1.54 0.29
10CRP (mg/dl) 1.24 ± 3.51 1.32 ± 1.76 0.44
1BMI Z-score (body mass index-z-score; 2SBP (systolic blood pressure);
3DBP (diastolic blood pressure); 4Tmax (time of maximum perfusion);
5TG (Triglycerides); 6TC (total cholesterol); 7HDL-C (high-density lipoprotein)-
cholesterol; 8LDL-C (low-density lipoprotein)-cholesterol; 9HOMA-IR (homeostatic
model assessment-insulin resistance); and 10CRP (C-reactive protein).
Table 2 Distributions of allele and genotype frequencies of NOS1 SNPs in children with and without endothelial
dysfunction
SNP Allele Endothelial function Endothelial dysfunction P-value OR CI 95%
n = 84 n = 38
rs6490121 A/G n % n %
AA 31 37 20 53 0.046 5.26 1.16-23.89
GA 34 40 16 42
GG 19 23 2 5
Allele A 96 57 56 74
Allele G 72 43 20 26
rs2293052 C/T n % n %
CC 53 63 16 42 0.016 1.76 0.46-6.71
TC 20 24 19 50
TT 11 13 3 8
Allele C 126 75 51 67
Allele T 42 25 25 33
rs3825102 A/C n % n %
AA 11 13 2 5 0.001 2.97 1.33-6.62
AC 22 26 23 61
CC 51 61 13 34
Allele A 44 26 27 36
Allele C 124 74 49 64
rs4767529 C/G n % n %
CC 44 52 12 32 0.049 1.28 0.38-4.31
GC 29 35 22 58
GG 11 13 4 10
Allele C 117 70 46 61
Allele G 51 30 30 39
rs561712 A/G n % n %
AA 13 15 4 10 0.037 2.34 1.03-5.32
AG 30 36 23 61
GG 41 49 11 29
Allele A 56 33 31 41
Allele G 112 67 45 59
rs549098 C/T n % n %
CC 43 51 11 29 0.032 1.21 0.40-3.67
TC 28 33 22 58
TT 13 16 5 13
Allele C 114 68 44 58
Allele T 54 32 32 42
rs567581 A/G n % n %
AA 13 16 5 13 0.022 2.70 1.19-6.14
AG 27 32 22 58
GG 44 52 11 29
Allele A 53 32 32 42
Allele G 115 68 44 58
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Table 2 Distributions of allele and genotype frequencies of NOS1 SNPs in children with and without endothelial
dysfunction (Continued)
rs483589 A/G n % n %
AA 11 13 11 29 0.008 3.58 1.47-8.70
AG 32 38 19 50
GG 41 49 8 21
Allele A 54 32 41 54
Allele G 114 68 35 46
rs693534 A/G n % n %
AA 11 13 13 34 0.011 2.67 1.15-6.18
AG 32 38 15 40
GG 41 49 10 26
Allele A 54 32 41 54
Allele G 114 68 35 46
rs9658255 C/G n % n %
CC 41 49 10 26 0.029 0.37 0.14-0.95
GC 32 38 17 45
GG 11 13 11 29
Allele C 114 68 37 49
Allele G 54 32 39 51
rs1879417 C/T n % n %
CC 14 17 14 37 0.02 2.73 1.07-6.91
CT 38 45 17 45
TT 32 38 7 18
Allele C 66 39 45 59
Allele T 102 61 31 41
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was evaluated by the Student’s t-test.
Statistical analysis
All analyses were conducted using SPSS software (ver-
sion 19.0; SPPS Inc., Chicago, Ill.), and data are
presented as mean ± SD. The association analysis was
assessed by using Pearson’s chi-square test implemented
in SPSS. A P-value < 0.05 was considered statistically
significant for all analyses. Odds ratio and 95% confi-
dence interval were calculated for the minor allele of
each SNP. We performed these analyses under the a
priori assumption that since candidate-gene studies lack
power to detect weak genetic risk effects of common
variants, any findings from the current analyses will re-
quire cautious interpretation. Indeed, to achieve a power
of >80% in the detection of a modest genetic risk (e.g.,
odds ratio = 1.2) for any SNP of interest with a known
prevalence of 10% in the population, a sample size of
more than 10,000 subjects would be needed [39,40]. The
Haploview version 4.2 software (hppt://www.borad.mit.
edu/mpg/haploview) was used to analyze the linkagedisequilibrium structure, calculating D’ to define haplo-
type block [41] and to estimate haplotype frequencies.
Additionally, pair-wise linkage disequilibrium (LD)
among the SNPs was examined using Lewontin’s stan-
dardized coefficient D’ and LD coefficient r2 [42], and
haplotype blocks were defined according to the method
of Garbriel et al. [41] in Haploview 4.2 with default set-
tings. Haplotypes within these blocks were estimated
using the estimation of maximization algorithm [43].
Results
Cohort phenotype
Of a potential total of 850 subjects, > 600 subjects were
recruited from the community, and of these, 122 chil-
dren were randomly selected and their endothelial func-
tion was tested (Figure 1). Approximately 245 subjects
were excluded from the study due to chronic medical
conditions such as Down syndrome, craniofacial or
known genetic syndromes, a known episode of infection
in the eight weeks preceding the sleep study, asthma or
allergies receiving specific therapy (desensitization, leu-
kotriene inhibitors, steroids (topical or systemic). Eighty
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dence of ED as defined by their individual Tmax values.
The demographic characteristics of these subjects are
shown in Table 1. The BMI- z score and the proportion
of obese children were significantly higher (P-value ≤
0.0002) in children with ED. However, there were no dif-
ferences in either systolic or diastolic blood pressures
between both groups. The metabolic data for the 2
groups are shown in Table 1. Only serum triglyceride
levels (TG) were significantly higher in children with ED
(P-value ≤ 0.04), with both groups exhibiting similar
fasting serum TC, HDL and LDL cholesterol. Similarly,
fasting glucose levels were similar, but plasma insulin(A)
(B)
Figure 2 Pairwise linkage disequilibrium (LD) structure and 11
SNPs of the NOS1 gene. Panel (A) represents children with normal
endothelial function (NEF), and Panel (B) represents children with
endothelial dysfunction (ED). The plot was generated using
Haploview 4.2 with D’ Color Scheme (D’ = 0, D’ < 1 and D’ = 1
shown by white, shades of pink and red (respectively) and pairwise
r2 values shown in diamonds. The value within each diamond
represents the pair-wise LD (correlation, measured as D’) between
the two SNPs defined by the top left and the top right of the
diamond. Solid lines represent SNPs that were used in the haplotype
analysis, and are part of the haplotype from SNP block whereas
dashed lines represent SNPs that were used in the analysis, but were
not part of the haplotype.concentrations were higher in ED children (P-value
≤0.05). Serum levels of high sensitivity C-reactive pro-
tein (hsCRP) were also similar (Table 1).NOS genes
As a preamble, all the SNPs tested in this study were in
Hardy-Weinberg equilibrium. From a total of 381 SNPs
assayed for the 3 NOS genes, 11 SNPs in NOS1
exhibited statistically significant differences in their fre-
quencies among children with and without ED both in
the univariate analysis and after correction for multiple
comparisons (Table 2). The P-value in Table 2 represents
the significance of the allele frequency for each SNP. In
addition, the odds ratio (OR) and the confidence inter-
vals of 95% (CI) for all SNPs are shown in Table 2. For
example, in addition, to the P-value for the allelic fre-
quency, if a SNP presented in Table 2 is higher than 1.0
that indicates this SNPs is significantly associated with
ED in the children. Furthermore, all SNPs in Table 2(A)
(B)
Figure 3 Haplotype frequencies in children with and without
endothelial dysfunction. Panel (A) represents haplotype for children
with normal endothelial function (NEF), and Panel (B) represents
haplotype for children with endothelial dysfunction (ED).
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one SNP (rs9658255), indicating that these SNPs are
most likely to be associated with ED. No differences
emerged for either NOS2 or NOS3 SNPs.
Linkage disequilibrium (LD) analysis of the 11 SNPs in
the NOS1 gene was assessed for both NEF and ED sub-
jects. In NEF subjects, two haplotype blocks emerged, and
are outlined in black triangular regions in Figure 2 (Panel
A). In ED subjects, the haplotype showed the presence of
2 blocks (Figure 2, Panel B). The haplotype of these blocks
and their frequencies in NEF and ED are shown inTable 3 Summary of genotypes-phenotypes for NOS1 SNPs th
Number of significant SNPs SNP Allele frequencies
1 rs6490121 *AA GA
(A/G) (n = 51) (n
Tmax *39.23 ± 22.10 39.
2 rs2293052 CC TC
(C/T) (n = 69) (n
Tmax 36.50 ± 19.02 42.
3 rs3825102 AA AC
(A/C) (n = 13) (n
Tmax 35.02 ± 20.82 43.
4 rs4767529 CC GC
(C/G) (n = 56) (n
Tmax 35.66 ± 16.94 41.
5 rs561712 AA AG
(A/G) (n = 17) (n
Tmax 35.26 ± 19.75 41.
6 rs549098 CC TC
(C/T) (n = 54) (n
Tmax 35.21 ± 16.44 42.
7 rs567581 AA AG
(A/G) (n = 18) (n
Tmax 36.61 ± 18.86 42.
8 rs483589 *AA AG
(A/G) (n = 22) (n
Tmax *42.88 ± 19.56 41.
9 rs693534 AA AG
(A/G) (n = 24) (n
Tmax 43.82 ± 19.41 38.
10 rs9658255 CC GC
(C/G) (n = 51) (n
Tmax 35.22 ± 20.80 39.
11 rs1879417 *CC CT
(C/T) (n = 28) (n
Tmax *45.55 ± 19.68 37.
*Indicates significant alleles.Figure 3, Panels A and B, respectively. Taken together, the
patterns of LD and haplotype frequencies differed between
NEF and ED, suggesting that some of these SNPs may
contribute to ED risk. Therefore, allelic data were analyzed
in conjunction with Tmax values among ED and NEF sub-
jects for the significant NOS1 SNPs as shown in Table 3.
Of the 11 significant SNPs of the NOS1 gene, there were
only 3 SNPs (rs6490121, rs483589, rs1879417) that
showed significantly different Tmax based on the geno-
type. We found that the A allele in rs6490121 (A/G) and
rs483589 (A/G) had significantly higher Tmax than the Gat were classified based on Tmax values in all children
*GG *AA + GA GG + GA
= 50) (n = 21) (n = 101) (n = 71)
99 ± 21.14 *31.55 ± 13.57 39.60 ± 21.53 37.49 ± 19.51
TT CC + TC TT + TC
= 39) (n = 14) (n = 108) (n = 53)
13 ± 23.15 35.80 ± 20.22 38.53 ± 20.68 40.45 ± 22.40
CC AA + AC CC + AC
= 45) (n = 64) (n = 58) (n = 109)
95 ± 24.46 34.84 ± 16.56 41.95 ± 23.82 38.60 ± 20.59
GG CC + GC GG + GC
= 51) (n = 15) (n = 107) (n = 66)
43 ± 24.04 36.84 ± 19.90 38.41 ± 20.74 40.39 ± 23.10
GG AA + AG GG + AG
= 53) (n = 52) (n = 70) (n = 105)
67 ± 23.43 35.66 ± 17.29 40.12 ± 22.62 38.70 ± 20.74
TT CC + TC TT + TC
= 50) (n = 18) (n = 104) (n = 68)
04 ± 24.54 36.61 ± 18.86 38.50 ± 20.91 40.60 ± 23.16
GG AA + AG GG + AG
= 49) (n = 55) (n = 67) (n = 104)
26 ± 24.75 35.14 ± 16.30 40.74 ± 23.31 38.50 ± 20.91
*GG *AA + AG GG + AG
= 51) (n = 49) (n = 73) (n = 100)
56 ± 23.18 *32.65 ± 16.88 *41.96 ± 22.02 37.19 ± 20.73
GG AA + AG GG + AG
= 47) (n = 51) (n = 71) (n = 98)
19 ± 20.74 35.61 ± 20.79 40.09 ± 20.34 36.85 ± 20.70
GG CC + GC GG + GC
= 49) (n = 22) (n = 100) (n = 71)
53 ± 20.53 42.24 ± 19.98 37.33 ± 20.68 40.37 ± 20.26
*TT CC + CT *TT + CT
= 55) (n = 39) (n = 83) (n = 94)
33 ± 21.45 *34.21 ± 18.97 40.10 ± 21.11 *36.03 ± 20.41
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http://www.translational-medicine.com/content/11/1/227allele (Figure 3, Panels A and B), while the C allele in
rs1879417 (C/T) had significantly higher Tmax values
compared to the T allele (Figure 4, Panel C).
Endothelin related genes
From a total of 155 available SNPs, there were only 2
SNPs in the EDN1 gene whose frequencies differed
among children with and without ED. The allele and
genotype frequencies of EDN1 SNPs are shown inFigure 4 Comparisons of allele frequencies (genotype) and Tmax valu
(A) represents NOS1 (rs6490121 A/G), Panel (B) represents NOS1 (rs483589
EDN1 (rs1476046 A/G) and Panel (E) represents EDN1 (rs4714384 C/T), respTable 4. These 2 EDN1 SNPs were analyzed in conjunc-
tion with corresponding Tmax values among ED and
NEF subjects. We found that both of these SNPs in
EDN1 (rs1476046, rs4714384) showed significant differ-
ences in Tmax based on genotype (Table 5). The G allele
in rs1476046 (A/G) had a significantly higher Tmax than
the A allele (Figure 4, Panel D), and the T allele in
rs4714384 (C/T) had a significantly higher Tmax than
the C allele (Figure 4, Panel E).es (phenotype) for the NOS1 and EDN1 significant SNPs. Panel
A/G), Panel (C) represents NOS1 (rs1879417 C/T), Panel (D) represents
ectively.
Table 4 Distributions of allele and genotype frequencies for EDN1 SNPs in children with and without endothelial
dysfunction
SNP Allele Endothelial function Endothelial dysfunction P-value OR CI 95%
n = 84 n = 38
rs1476046 A/G n % n %
AA 2 2 1 3 0.032 0.34 0.15-0.79
AG 41 49 9 24
GG 41 49 28 73
Allele A 45 27 11 15
Allele G 123 73 65 85
rs4714384 C/T n % n %
CC 22 26 3 8 0.016 0.38 0.16-0.86
CT 44 52 19 50
TT 18 22 16 42
Allele C 88 52 25 33
Allele T 80 48 51 67
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To confirm the SNP array-based findings, we performed
qRT-PCR using TaqMan assays with specific primers for
some of the SNPs of interest, i.e., those with significantly
different frequencies in their allelic genotype frequencies
(Additional file 1: Table S1), as well as some of those
with significantly different genotype-phenotype allelic
frequencies (Additional file 1: Table S1). The concord-
ance findings between array and real-time PCR for allele
and genotype frequencies of NOS1 and EDN1 SNPs in
children with and without ED are shown in Additional
file 2: Table S2. The concordance for both SNPs in the
NOS1 gene (rs3825102, rs483589) was 53.21%, and
61.47%, respectively and 49% for EDN1 SNPS (rs1476046,
rs4714384). The summary of the validated SNPs data for
both NOS1 and EDN1 genes between SNPs array and
qRT-PCR is shown in Additional file 3: Table S3.
qRT-PCR gene expression
Next we asked how the SNPs that putatively affected
endothelial function, specifically, their association with
gene expression. We selected a total of 20 matched sub-
jects, 10 with endothelial dysfunction (ED), and 10 withTable 5 Summary of genotypes-phenotypes for EDN1 SNPs th
Number of significant SNPs SNP Allele frequencies
1 EDN1 AA
rs1476046(A/G) (n = 3)
Tmax 37.13 ± 18.47
2 EDN1 CC
rs4714384 (C/T) (n = 25)
Tmax 37.08 ± 23.65
*Indicates significant alleles.normal endothelial function (NEF), and performed gene
expression analysis using qRT-PCR. A significant in-
crease in EDN1 gene expression in the peripheral blood
of children with ED emerged compared to NEF as illus-
trated in Figure 5 (P-value 0.0004).
Discussion
In this study, we report on the associations between the
frequency of the 3 NOS genes, and 3 genes of the EDN
family, along with its two cognate receptors in a carefully
phenotyped cohort of pre-pubertal otherwise healthy com-
munity children with and without ED. Not surprisingly, an
increased risk of obesity and of increased serum TG levels
was present in children with ED. The latter may underlie
previously reported lower nitric oxide levels in the context
of elevated TG [44]. In addition, the relative frequencies of
only a selected few NOS1 and EDN1 gene polymorphisms
differed among children with ED, and assessment of Tmax
based on allelic variants further confirmed a higher risk of
increased Tmax among those children harboring the poly-
morphic allele.
Before we discuss the potential significance of our
findings, some of the strengths and limitations of theat were classified based on Tmax values in all children
AG *GG *AA + AG GG + AG
(n = 50) (n = 69) (n = 53) (n = 119)
31.89 ± 19.20 *42.85 ± 20.62 *32.19 ± 19.03 38.25 ± 20.68
CT *TT *CC + CT TT + CT
(n = 63) (n = 34) (n = 88) (n = 97)
34.53 ± 17.56 *45.89 ± 21.82 *35.25 ± 19.38 38.51 ± 19.81
NEF ED
1.5
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Figure 5 Real-time PCR analysis for EDN1 gene expression in
children with normal endothelial function (NEF) and endothelial
dysfunction (ED). Total RNA was isolated from peripheral blood and
transcribed into cDNA. The data presented as mRNA expression
levels normalized to 18 s ribosomal RNA concentrations. Results are
presented as individual values and as boxplots (P-value < 0.0004).
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http://www.translational-medicine.com/content/11/1/227study should be mentioned. First, the use of the laser
Doppler technique for assessment of vascular responses
following cuff-induced arterial occlusion not only allows
reproducible determinations of the kinetics of post-
ischemic reperfusion, but also provides an accurate re-
porter of NO-mediated physiological recruitment of the
microvasculature [34,45]. The selection of the 60-seconds
occlusion time, rather than the more extensively used 5
minutes in adults, was necessary based on a vast set of
preliminary experiments aimed at preventing motion-
induced artifacts, and thus preserving the validity of the
tests. In addition, all Tmax assessments were conducted
in the fasting state at the same time of the day to minimize
potential confounders introduced by differences in meal
content and timing relative to the testing, and also to en-
sure that circadian variation in endothelial function would
not play a role. An additional strength of the study was
the inclusion of a priori healthy children from the com-
munity. In addition, we excluded children with a variety of
diagnoses that can be associated with endothelial dysfunc-
tion [46]. Two important limitations of this study include
the relatively small size of the cohort of children studied
which could hamper statistical power, and the absence of
endothelin plasma level measurements. However, these
data may be incorporated into multicenter-based meta-
analyses that will undoubtedly enhance the validity of the
present putative findings. Finally, in the context of our
qRT-pCR validation efforts using TaqMan SNP assays, we
found substantial discrepancies between the two methods
(i.e., SNP arrays and qRT-PCR), even if the significance of
the findings remained unaltered. The concordance
between the array data and qRT-PCR revolved around
only 50-60%. This was surprising considering that theconcordance between gene expression arrays and qRT-
PCR is remarkably high. It therefore appears that this may
not be case for SNP arrays, and the discordant findings
necessarily mandate that future studies should require an
additional validation step of the array findings using alter-
native methodologies, an approach that has not been pur-
sued to date while using the same 50 k SNP array as used
herein or other commercially available arrays [47-50].
Obesity is a prominent risk factor for the development
of cardiovascular disease, diabetes mellitus, dyslipidemia,
hypertension, and their constellation as the metabolic
syndrome in both adults and children [51-55]. We and
others have previously shown that obese children are at
higher risk for ED and that both the vasodilatory and
vasoconstrictive responses are important. Interestingly,
in a recent study Tounian and colleagues reported their
analyses of a cohort of 232 severely obese children in
whom 12 gene polymorphisms representing selected var-
iants previously associated with vascular ED in adults
were examined [56]. These investigators did not find any
significant association between flow-mediated vasodila-
tion and any of the 12 SNPs studied. Based on our
current findings, we propose that the increased risk for
ED in obesity may be explained at least in part by the
presence of gene variants in NOS and EDN.
Several studies have investigated the NOS genes family
SNPs in relation to different diseases, primarily involving
the cardiovascular system [57-60]. In the present study,
we found 11 SNPs in the NOS1 gene showing significant
differences between children with and without ED. In
addition, out of these 11 SNPs, we found 3 SNPs
(rs6490121, rs483589, and rs1879417) that were signifi-
cantly associated with altered Tmax values in children,
suggesting that these SNPs carry biological significance.
However, no significant differences or associations among
SNPs in either NOS2 or NOS3 genes were found.
Similar to studies on NOS gene SNPs, several studies
suggest that some of the EDN1 SNPs may be associated
with hypertension. For example, EDN1 SNP (rs5370)
Lys198Asn (G/T), interactions between BMI and blood
pressure emerged in overweight/obese subjects [61-64].
This non-synonymous SNP has already been associated
with heart failure and hypertension [61,65]. Further-
more, in rheumatoid arthritis patients who carry the T-T
haplotype in EDN1 SNPs (rs1800541 and rs5370),
increased systolic blood pressure and high EDN1 plasma
levels emerged [66]. In this study, we identified 2
significant SNPs (rs1476046, rs4714384) in the EDN1
gene, and both of these SNPs showed significant differ-
ences in Tmax values, adding corroborative evidence to
the assumption that these SNPs have biological signifi-
cance. However, no significant differences emerged in
the allelic frequencies in EDN2, EDN3, EDNRA, and
EDNRB.
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http://www.translational-medicine.com/content/11/1/227In summary, significant associations of polymorphisms
in NOS and EDN genes are apparent among young chil-
dren with ED. Of note, EDN1 gene expression appears
to be increased in the context of ED. Accordingly; fur-
ther functional studies are needed to clarify the role of
variants of NOS and EDN genes in the pathophysiology
of cardiovascular disease.
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